|
1
|
Meyer zu Schwabedissen HE and Kroemer HK:
In vitro and in vivo evidence for the importance of breast cancer
resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp
Pharmacol. 201:325–371. 2011.PubMed/NCBI
|
|
2
|
Jones K, Bray PG, Khoo SH, Davey RA,
Meaden ER, Ward SA and Back DJ: P-glycoprotein and transporter MRP1
reduce HIV protease inhibitor uptake in CD4 cells: potential for
accelerated viral drug resistance? AIDS. 15:1353–1358. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ni Z, Bikadi Z, Rosenberg MF and Mao Q:
Structure and function of the human breast cancer resistance
protein (BCRP/ABCG2). Curr Drug Metab. 11:603–617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nicolazzo JA and Katneni K: Drug transport
across the blood-brain barrier and the impact of breast cancer
resistance protein (ABCG2). Curr Top Med Chem. 9:130–147. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou S, Morris JJ, Barnes Y, Lan L,
Schuetz JD and Sorrentino BP: Bcrp1 gene expression is required for
normal numbers of side population stem cells in mice, and confers
relative protection to mitoxantrone in hematopoietic cells in vivo.
Proc Natl Acad Sci USA. 99:12339–12344. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim RB, Leake BF, Choo EF, Dresser GK,
Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, et al:
Identification of functionally variant MDR1 alleles among European
Americans and African Americans. Clin Pharmacol Ther. 70:189–199.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cisternino S, Mercier C, Bourasset F, Roux
F and Scherrmann JM: Expression, up-regulation, and transport
activity of the multidrug-resistance protein Abcg2 at the mouse
blood-brain barrier. Cancer Res. 64:3296–3301. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cooray HC, Blackmore CG, Maskell L and
Barrand MA: Localisation of breast cancer resistance protein in
microvessel endothelium of human brain. Neuroreport. 13:2059–2063.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maliepaard M, Scheffer GL, Faneyte IF, van
Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper
RJ and Schellens JH: Subcellular localization and distribution of
the breast cancer resistance protein transporter in normal human
tissues. Cancer Res. 61:3458–3464. 2001.PubMed/NCBI
|
|
10
|
Gupta A, Zhang Y, Unadkat JD and Mao Q:
HIV protease inhibitors are inhibitors but not substrates of the
human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol
Exp Ther. 310:334–341. 2004. View Article : Google Scholar
|
|
11
|
Wang X, Furukawa T, Nitanda T, Okamoto M,
Sugimoto Y, Akiyama S and Baba M: Breast cancer resistance protein
(BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside
reverse transcriptase inhibitors. Mol Pharmacol. 63:65–72. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang X, Nitanda T, Shi M, Okamoto M,
Furukawa T, Sugimoto Y, Akiyama S and Baba M: Induction of cellular
resistance to nucleoside reverse transcriptase inhibitors by the
wild-type breast cancer resistance protein. Biochem Pharmacol.
68:1363–1370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rehermann B and Naoumov NV: Immunological
techniques in viral hepatitis. J Hepatol. 46:508–520. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
König J, Hartel M, Nies AT, Martignoni ME,
Guo J, Büchler MW, Friess H and Keppler D: Expression and
localization of human multidrug resistance protein (ABCC) family
members in pancreatic carcinoma. Int J Cancer. 115:359–367.
2005.PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCRand
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
16
|
Doyle LA, Yang W, Abruzzo LV, Krogmann T,
Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter
from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA.
95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee CG and Gottesman MM: HIV-1 protease
inhibitors and the MDR1 multidrug transporter. J Clin Invest.
101:287–288. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Srinivas RV, Middlemas D, Flynn P and
Fridland A: Human immunodeficiency virus protease inhibitors serve
as substrates for multidrug transporter proteins MDR1 and MRP1 but
retain antiviral efficacy in cell lines expressing these
transporters. Antimicrob Agents Chemother. 42:3157–3162. 1998.
|
|
19
|
Schuetz JD, Connelly MC, Sun D, Paibir SG,
Flynn PM, Srinivas V, Kumar A and Fridland A: MRP4: A previously
unidentified factor in resistance to nucleoside-based antiviral
drugs. Nat Med. 5:1048–1051. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huisman MT, Smit JW and Schinkel AH:
Significance of P-glycoprotein for the pharmacology and clinical
use of HIV protease inhibitors. AIDS. 14:237–242. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Poller B, Wagenaar E, Tang SC and Schinkel
AH: Double-transduced MDCKII cells to study human P-glycoprotein
(ABCB1) and breast cancer resistance protein (ABCG2) interplay in
drug transport across the blood-brain barrier. Mol Pharm.
8:571–582. 2011. View Article : Google Scholar
|
|
22
|
Reid G, Wielinga P, Zelcer N, De Haas M,
Van Deemter L, Wijnholds J and Borst P: Characterization of the
transport of nucleoside analog drugs by the human multidrug
resistance proteins MRP4 and MRP5. Mol Pharmacol. 63:1094–1103.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Borst P, Balzarini J, Ono N, Reid G, de
Vries H, Wielinga P, Wijnholds J and Zelcer N: The potential impact
of drug transporters on nucleoside-analog-based antiviral
chemotherapy. Antiviral Res. 62:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Janneh O, Owen A, Chandler B, Hartkoorn
RC, Hart CA, Bray PG, Ward SA, Back DJ and Khoo SH: Modulation of
the intracellular accumulation of saquinavir in peripheral blood
mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS.
19:2097–2102. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
de Maat MM, Ekhart GC, Huitema AD, Koks
CH, Mulder JW and Beijnen JH: Drug interactions between
antiretroviral drugs and comedicated agents. Clin Pharmacokinet.
42:223–282. 2003.PubMed/NCBI
|
|
26
|
Huisman MT, Smit JW, Wiltshire HR,
Hoetelmans RM, Beijnen JH and Schinkel AH: P-glycoprotein limits
oral availability, brain, and fetal penetration of saquinavir even
with high doses of ritonavir. Mol Pharmacol. 59:806–813
|
|
27
|
Perloff ES, Duan SX, Skolnik PR,
Greenblatt DJ and von Moltke LL: Atazanavir: effects on
P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab
Dispos. 33:764–770. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding R, Tayrouz Y, Riedel KD, Burhenne J,
Weiss J, Mikus G and Haefeli WE: Substantial pharmacokinetic
interaction between digoxin and ritonavir in healthy volunteers.
Clin Pharmacol Ther. 76:73–84. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hayashi K, Pu H, Tian J, Andras IE, Lee
YW, Hennig B and Toborek M: HIV-Tat protein induces P-glycoprotein
expression in brain microvascular endothelial cells. J Neurochem.
93:1231–1241. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hayashi K, Pu H, Andras IE, Eum SY,
Yamauchi A, Hennig B and Toborek M: HIV-TAT protein upregulates
expression of multidrug resistance protein 1 in the blood-brain
barrier. J Cereb Blood Flow Metab. 26:1052–1065. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jorajuria S, Dereuddre-Bosquet N,
Naissant-Storck K, Dormont D and Clayette P: Differential
expression levels of MRP1, MRP4, and MRP5 in response to human
immunodeficiency virus infection in human macrophages. Antimicrob
Agents Chemother. 48:1889–1891. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Turriziani O, Gianotti N, Falasca F, Boni
A, Vestri AR, Zoccoli A, Lazzarin A and Antonelli G: Expression
levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood
mononuclear cells from HIV infected patients failing ART. J Med
Virol. 80:766–771. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lucia MB, Savarino A, Straface E, Golotta
C, Rastrelli E, Matarrese P, Rotella S, Malorni W and Cauda R: Role
of lymphocyte multidrug resistance protein 1 in HIV infection:
expression, function, and consequences of inhibition. J Acquir
Immune Defic Syndr. 40:257–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Meaden ER, Hoggard PG, Maher B, Khoo SH
and Back DJ: Expression of P-glycoprotein and multidrug
resistance-associated protein in healthy volunteers and
HIV-infected patients. AIDS Res Hum Retroviruses. 17:1329–1332.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Speck RR, Yu XF, Hildreth J and Flexner C:
Differential effects of p-glycoprotein and multidrug resistance
protein-1 on productive human immunodeficiency virus infection. J
Infect Dis. 186:332–340. 2002. View
Article : Google Scholar
|
|
36
|
Gupta S and Gollapudi S: P-glycoprotein
(MDR 1 gene product) in cells of the immune system: its possible
physiologic role and alteration in aging and human immunodeficiency
virus-1 (HIV-1) infection. J Clin Immunol. 13:289–301. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Laupèze B, Amiot L, Payen L, Drénou B,
Grosset JM, Lehne G, Fauchet R and Fardel O: Multidrug resistance
protein (MRP) activity in normal mature leukocytes and
CD34-positive hematopoietic cells from peripheral blood. Life Sci.
68:1323–1331. 2001.PubMed/NCBI
|
|
38
|
Albermann N, Schmitz-Winnenthal FH,
Z’graggen K, Volk C, Hoffmann MM, Haefeli WE and Weiss J:
Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1,
MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear
cells and their relationship with the expression in intestine and
liver. Biochem Pharmacol. 70:949–958. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oselin K, Mrozikiewicz PM, Pähkla R and
Roots I: Quantitative determination of the human MRP1 and MRP2 mRNA
expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and
CD56+ cells. Eur J Haematol. 71:119–123. 2003. View Article : Google Scholar
|
|
40
|
Turriziani O, Di Marco P, Antonelli G and
Dianzani F: May the drug transporter P glycoprotein affect the
antiviral activity of human immunodeficiency virus type 1
proteinase inhibitors? Antimicrob Agents Chemother. 44:473–474.
2000. View Article : Google Scholar : PubMed/NCBI
|
